Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 3Thoracic 1Head & Neck 1Breast 1

Conditions

Salivary Gland Neoplasms 1Carcinoma, Adenoid Cystic 1

Interventions

Cisplatin 47pembrolizumab 37Magnetic Resonance Spectroscopy 33Specimen Handling 27Radiotherapy, Intensity-Modulated 21Cetuximab 19Nivolumab 18Carboplatin 16Platinum 151,2-diaminocyclohexaneplatinum II citrate 15Radiotherapy 14Biopsy 12Paclitaxel 11Gemcitabine 10Docetaxel 10Surveys and Questionnaires 9Radiation 9Immunoglobulin G 7Disulfides 7toripalimab 6cemiplimab 6Ipilimumab 6Fluorouracil 6Bevacizumab 6dostarlimab 5atezolizumab 5Watchful Waiting 5Taxes 5Immune Checkpoint Inhibitors 5Drug Therapy 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glutamate Carboxypeptidase II × Head & Neck × 30 days × Clear all
NCT04895735 2026-06-04

MC200708 Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer

Mayo Clinic

Phase 2 Active not recruiting
45 enrolled 12 charts
Head & Neck

Carcinoma, Adenoid Cystic, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡